When medicine leaves a gap, people fill it themselves, with whatever is legal, cheap, and within reach.

The DEA moved to ban 7-OH, a potent compound derived from kratom and now sold in concentrated form. Kratom, the Southeast Asian plant, has been used by millions of Americans for pain and to escape opioids. The last time the DEA tried to schedule it, in 2016, public backlash forced the agency to retreat.

The pharmacology matters here. Kratom’s active alkaloids, mitragynine and its more potent metabolite 7-OH, act as partial agonists at the same receptors as opioids, which is why the plant can blunt withdrawal and pain. The new concern is products concentrating 7-OH far beyond anything in the leaf. The plant and the isolate are not the same substance, and treating them as one is the whole error.

The case for the ban is that concentrated 7-OH is a genuinely different animal — potent, opioid-like, capable of real dependence, and sold with no standards or dosing.

The case against is that a blanket prohibition sweeping in the plant repeats the 2016 mistake. It pushes people who use kratom to stay off heroin and fentanyl back toward the drugs that are killing them, with no evidence that prohibition improves a single outcome. Everything the opioid era taught about harm reduction argues against it.

Prohibition falls hardest on the self-medicating poor — the people reaching for a legal plant precisely because the medical system priced them out of the alternatives.

The honest position is neither harmless herb nor just an opioid. It is that regulation should match evidence, and the evidence says the concentrated isolate and the raw leaf deserve different answers. Matching the rule to the data, not the panic, is the argument we keep pressing at Popular Rationalism.

American Life is independent analysis.